<DOC>
	<DOCNO>NCT00186329</DOCNO>
	<brief_summary>Many patient exacerbation heart failure significant concomitant kidney dysfunction . The combination two condition make pharmacological management difficult . In study , plan randomize patient heart failure kidney dysfunction receive infusion Natrecor ( B-type Natriuretic Peptide ) -- may beneficial management two disease -- placebo .</brief_summary>
	<brief_title>BNP Cardio-Renal Decompensation Syndrome ( BNP-CARDS )</brief_title>
	<detailed_description>Heart failure represent grow epidemic United States . Recent figure reveal almost 5 million people heart failure U.S. alone , incidence ( 550,000 new diagnoses/year ) increase threefold last 25 year . This grow incidence heart failure think due change population demographic . Rates major risk factor disease-diabetes mellitus , hypertension , renal insufficiency -- steadily increase . Renal insufficiency cause particular difficulty management heart failure . Most CHF patient significant degree renal insufficiency - risk factor two disease , also reduce cardiac output relate CHF lead reduce glomerular filtration rate ( GFR ) . Diuretics escalate dos , cornerstone therapy CHF exacerbation , also lead worsen renal function , continue inability achieve adequate diuresis toxicity agent give . B-type Natriuretic Peptide ( BNP ) 32-amino acid peptide hormone secrete predominantly ventricles response increase pressure volume . It several action vivo , work diuretic , natriuretic systemic pulmonary vasodilator . Natrecor recombinant peptide structurally identical endogenous BNP , approve treatment decompensated heart failure . In Vasodilation management Acute Congestive Heart Failure ( VMAC ) trial , therapy Natrecor result improvement pulmonary capillary wedge pressure see within 15 minute start therapy ; improvement significantly well intravenous nitroglycerine . Patients also report great improvement dyspnea Natrecor therapy placebo . In prior study , group demonstrate prolonged Natrecor infusion result improve hemodynamic parameter Stage D heart failure patient await heart transplantation . Natrecor therapy hold theoretical value patient heart failure concomitant renal insufficiency . Prior experimental work demonstrate BNP infusion increase diuresis , natriuresis , importantly , GFR healthy subject -- represent major objective therapy heart failure patient . Many also report clinical experience renal function preserve , diuresis/natriuresis readily achieve patient heart failure exacerbation renal insufficiency addition Natrecor therapy . However , potential use Natrecor rigorously test . The study prospective , double-blinded , placebo control clinical trial . Patients admit medical diagnosis CHF exacerbation meet study criterion randomize receive Natrecor v placebo ( 5 % dextrose water ) intravenous infusion 48 hrs.Randomization occur pharmacy department . Patients randomize Natrecor receive 2mcg/kg IV bolus , follow continuous infusion 0.01mcg/kg/min . ( Patients net negative diuresis great 1 liter prior initiation Natrecor therapy receive bolus dose give great risk hypotension ) . Those randomized placebo receive dummy bolus infusion volume 5 % dextrose water . 100 subject recruit . Inclusion criterion include inpatient admission diagnosis CHF exacerbation calculate creatinine clearance 15-60 ml/min use Cockcroft-Gault equation . Patients 18 year older eligible trial regardless gender ethnic background . Exclusion criterion include : hypotension ( SBP &lt; 90mmHg ) time enrollment , severe hypertension ( SBP &gt; 170 mmHg ) necessitate IV vasodilator therapy , know allergy Natrecor , history heart transplantation , up-front use inotropes , contraindication vasodilator therapy ( severe aortic stenosis ) , mental incompetence meaning inability provide inform consent . In addition Stanford University Medical Center , begin data collection VA Hospital Palo Alto , CA . Initial nursing management subject include every 15 minute blood pressure monitor hypotension . In case , IV infusion discontinue 36 minute ( half-life Natrecor 18 minute ) restart . Clinical experience Natrecor proven regime usually effective .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>acute admission hospital CHF exacerbation calculate creatinine clearance 1560ml/min use Cockroft Gault equation . hypotension ( SBP &lt; 90mmHg ) hypertension ( SBP &gt; 170 mmHg ) necessitate vasodilator therapy know allergy Natrecor history heart transplantation contraindication vasodilator therapy ( i.e . severe aortic stenosis ) upfront use inotropes mental incompetence meaning inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vasodilation</keyword>
	<keyword>Congestive heart failure</keyword>
	<keyword>Renal insufficiency</keyword>
	<keyword>Diuresis</keyword>
	<keyword>Serum creatinine</keyword>
</DOC>